<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Soc Trans</journal-id><journal-id journal-id-type="iso-abbrev">Biochem. Soc. Trans</journal-id><journal-id journal-id-type="hwp">ppbiost</journal-id><journal-id journal-id-type="publisher-id">BST</journal-id><journal-title-group><journal-title>Biochemical Society Transactions</journal-title></journal-title-group><issn pub-type="ppub">0300-5127</issn><issn pub-type="epub">1470-8752</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26517901</article-id><article-id pub-id-type="pmc">4613533</article-id><article-id pub-id-type="publisher-id">BST20150096</article-id><article-id pub-id-type="doi">10.1042/BST20150096</article-id><article-categories><subj-group subj-group-type="heading"><subject>Biochemical Society Focused Meetings</subject><subj-group><subject>ATP binding cassette transporters: from mechanism to organism</subject></subj-group></subj-group><subj-group subj-group-type="overline"><subject>ATP binding cassette transporters: from mechanism to organism</subject></subj-group><subj-group subj-group-type="Primary"><subject>S4</subject></subj-group></article-categories><title-group><article-title>Molecular action of sulphonylureas on K<sub>ATP</sub> channels: a real partnership between drugs and nucleotides</article-title><alt-title alt-title-type="right-running-head">ATP-binding cassette transporters: from mechanism to organism</alt-title><alt-title alt-title-type="left-running-head">Biochemical Society Transactions (2015) Volume 43, part 5</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Wet</surname><given-names>Heidi</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Proks</surname><given-names>Peter</given-names></name><xref ref-type="corresp" rid="COR1"><sup>1</sup></xref><xref ref-type="aff" rid="A1">*</xref></contrib><aff id="A1"><label>*</label>Department of Physiology, Anatomy and Genetics, Le Gros Clark building, University of Oxford, South Parks Road, Oxford OX1 3QX, England, U.K.</aff></contrib-group><author-notes><corresp id="COR1"><bold><sup>1</sup>To whom correspondence should be addressed (email</bold><email>peter.proks@dpag.ox.ac.uk</email><bold>)</bold>.</corresp></author-notes><pub-date pub-type="epub"><day>9</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="ppub"><day>1</day><month>10</month><year>2015</year></pub-date><volume>43</volume><issue>5</issue><issue-id pub-id-type="display">5</issue-id><fpage>901</fpage><lpage>907</lpage><history><date date-type="received"><day>30</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Authors; published by Portland Press Limited</copyright-statement><copyright-year>2015</copyright-year></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="bst0430901.pdf"/><abstract><p>Sulphonylureas stimulate insulin secretion from pancreatic &#x003b2;-cells primarily by closing ATP-sensitive K<sup>+</sup> channels in the &#x003b2;-cell plasma membrane. The mechanism of channel inhibition by these drugs is unusually complex. As direct inhibitors of channel activity, sulphonylureas act only as partial antagonists at therapeutic concentrations. However, they also exert an additional indirect inhibitory effect via modulation of nucleotide-dependent channel gating. In this review, we summarize current knowledge and recent advances in our understanding of the molecular mechanism of action of these drugs.</p></abstract><kwd-group kwd-group-type="kwd"><kwd>ABCC8</kwd><kwd>diabetes</kwd><kwd>KATP channels</kwd><kwd>Kir6.2</kwd><kwd>SUR1</kwd></kwd-group><counts><fig-count count="3"/><ref-count count="45"/><page-count count="7"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Sulphonylurea drugs have been used for over 60&#x000a0;years to treat type&#x000a0;2 diabetes [<xref rid="B1" ref-type="bibr">1</xref>]. These drugs share a common mechanism of action, which is also the case for the previously developed anti-hyperglycaemic drugs, glinides [<xref rid="B2" ref-type="bibr">2</xref>]. Their primary target is the ATP-sensitive potassium (K<sub>ATP</sub>) channel which controls plasma membrane potential in the pancreatic &#x003b2;-cells [<xref rid="B3" ref-type="bibr">3</xref>]. Binding of sulphonylureas to K<sub>ATP</sub> channel induces channel closure [<xref rid="B4" ref-type="bibr">4</xref>]. This causes membrane depolarization, which activates voltage-dependent Ca<sup>2+</sup> channels in the &#x003b2;-cell plasma membrane and the resulting Ca<sup>2+</sup> influx triggers Ca<sup>2+</sup>-dependent insulin granule exocytosis.</p><p>In addition to their action on the K<sub>ATP</sub> channel, sulphonylureas can also stimulate insulin secretion independently of changing the membrane potential via interactions with proteins within the exocytotic pathway [<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>].</p></sec><sec><title>The B-cell K<sub>ATP</sub> channel and sulphonylureas</title><p>The &#x003b2;-cell K<sub>ATP</sub> channel couples glucose metabolism to &#x003b2;-cell electrical activity. Gating (opening and closing) of these channels is primarily determined by intracellular concentrations of adenosine nucleotides (nts). Under Mg<sup>2+</sup>-free conditions, unchelated ATP (and ADP) inhibits K<sub>ATP</sub> channels through binding to the pore-forming subunit of the channel complex; it is important to note that this inhibitory ligand-binding site does not discriminate between the chelated and unchelated forms of ATP. On the contrary, chelated MgADP (or MgATP) stimulates channel activity through specific interaction with the nt-binding domains of a regulatory subunit of the channel [(sulphonylurea receptor (SUR)], counteracting these nts&#x02019; simultaneous inhibitory effect at the channel pore [<xref rid="B7" ref-type="bibr">7</xref>].</p><p>The K<sub>ATP</sub> channel is a hetero-octameric complex composed of four Kir6.2 subunits and four SUR subunits [<xref rid="B8" ref-type="bibr">8</xref>]. Kir6.2 (<italic>KCNJ11</italic>) is a member of the inwardly rectifying K-channel family; it possesses a potassium-selective pore and an inhibitory site for (Mg)ATP [<xref rid="B9" ref-type="bibr">9</xref>]. SURs are members of the C subfamily of the ABC (ATP-binding cassette) superfamily [<xref rid="B10" ref-type="bibr">10</xref>]. There are three isoforms of the SUR: <italic>ABCC8</italic>/SUR1 is expressed in pancreas and neurons, <italic>ABCC9</italic>/SUR2A in skeletal and cardiac muscle and a splice variant of <italic>ABCC9</italic>, called SUR2B, in smooth muscle and brain. The major regulatory role of SURs is to mediate stimulation by Mg&#x02013;adenosine nts via their two nt-binding domains: nt-binding domain 1 (NBD1) and nt-binding domain 2 (NBD2). Nt binding to SURs causes head-to-tail dimerization of the NBDs and formation of two nt-binding sites [NBS1 (nt-binding site 1) and NBS2 (nt-binding site 2)] within the dimer interface. NBS2 possesses greater ATPase activity than NBS1; and its occupancy by MgADP stimulates K<sub>ATP</sub> channel activity [<xref rid="B11" ref-type="bibr">11</xref>]<bold>.</bold> Available data indicate that MgATP promotes channel opening only via its hydrolysis to MgADP [<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>]; in this aspect, regulation of K<sub>ATP</sub> channel activity by NBSs of SUR differs from that of other ABC proteins such as CFTR (cystic fibrosis transmembrane conductance regulator) (<italic>ABCC7</italic>) or P-gp (P-gap, <italic>ABCB1</italic>) where conformational changes induced by MgATP binding [<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>] result in promotion of channel opening (CFTR) or stimulation of drug transport (P-gp).</p><p>K<sub>ATP</sub> channels possess both high-affinity- and low-affinity-binding sites for sulphonylureas and glinides. The precise locations of these binding sites are currently unknown. The high affinity site involves intracellular loops of SUR between transmembrane domains (TMs) 5 and 6 [<xref rid="B18" ref-type="bibr">18</xref>] and TMs 15 and 16 [<xref rid="B19" ref-type="bibr">19</xref>]. N-terminus of Kir6.2 is also involved in binding of the sulphonylurea glibenclamide and the glinide repaglinide [<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>].</p></sec><sec><title>Direct inhibitory effect of sulphonylureas</title><p>Consistent with the existence of two distinct binding sites, sulphonylurea concentration-inhibition curve for K<sub>ATP</sub> channels measured in excised patches in the absence of nts is biphasic (<xref ref-type="fig" rid="F1">Figure 1</xref>A). The low-affinity block resides on Kir6.2 subunit; the high-affinity site is present only when Kir6.2 is co-expressed with SUR [<xref rid="B22" ref-type="bibr">22</xref>]. The low-affinity site is of no clinical relevance as it is occupied only at concentrations much higher than those found in the plasma of patients treated with sulphonylureas [<xref rid="B23" ref-type="bibr">23</xref>]. In the absence of intracellular nts, the maximal extent of high-affinity inhibition is only 50%&#x02013;80%, depending on the type&#x000a0;of sulphonylurea [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>]. Thus, sulphonylureas bound to the high-affinity site act only as partial antagonists so that the channel remains open for a substantial fraction of time when the high-affinity-binding sites are fully occupied.</p><fig id="F1" position="float"><label>Figure 1</label><caption><title>Direct and indirect inhibitory effects of sulphonylureas.</title><p>(<bold>A</bold>) Gliclazide concentration-inhibition curves for wild-type &#x003b2;-cell K<sub>ATP</sub> currents in excised patch (nt-free solution) and in intact cell (nt present), as indicated. The data is plotted as the current measured in the presence of the drug (<italic>I</italic>) expressed as a fraction of current in its absence (<italic>I</italic><sub>C</sub>). The fitting parameters were published previously in Proks et al. [<xref rid="B4" ref-type="bibr">4</xref>]. The line for data obtained for excised patches is drawn according to equation: <inline-graphic xlink:href="bst0430901tg1.jpg" id="tg1"/> where <italic>IC<sub>50,1</sub></italic>=51&#x000a0;nM and <italic>IC<sub>50,2</sub></italic>=3.1&#x000a0;mM are the half-maximal inhibitory concentrations at the high- and low-affinity sites respectively; <italic>h<sub>1</sub>=</italic> 1.0 and <italic>h<sub>2</sub>=</italic> 1.0 are the Hill coefficients for the high- and low-affinity sites respectively; and <italic>a=</italic> 0.4 is the fraction of sulphonylurea-resistant current when all high-affinity sites are occupied. The line for data obtained for intact cell is drawn according to the below equation [<xref rid="B4" ref-type="bibr">4</xref>]: <inline-graphic xlink:href="bst0430901tg2.jpg" id="tg2"/> where IC<sub>50</sub>=108&#x000a0;nM is the half-maximal inhibitory concentration and <italic>h</italic>=0.81 is the Hill coefficient. (<bold>B</bold>) Relationship between the fraction of gliclazide-resistant current produced by the direct high-affinity inhibition of the drug (mechanism <italic>I</italic> in <bold>A</bold>) and single-channel P<sub>O</sub> simulated for K<sub>ATP</sub> currents with a simple concerted gating model (Monod&#x02013;Wyman&#x02013;Changeux model) [<xref rid="B25" ref-type="bibr">25</xref>]. The P<sub>O</sub> of wild-type K<sub>ATP</sub> channels in excised patches after fast rundown was taken as 0.4 [<xref rid="B24" ref-type="bibr">24</xref>]. P<sub>O</sub> is primary determined by the stability of channel open state; it can be reduced by factors such as channel rundown or increased by channel mutations or via Mg-nt activation of the channel [<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B35" ref-type="bibr">35</xref>]. (<bold>C</bold> and <bold>D</bold>) Schematic showing effects of nts (<bold>C</bold> and <bold>D</bold>) and of nts and sulphonylureas (<bold>D</bold>) on the wild-type &#x003b2;-cell K<sub>ATP</sub> channel. For clarity, all four subunits of the Kir6.2 tetramer but only one SUR1 subunit (out of the four) are shown. ATP binding (both chelated and unchelated form) to Kir6.2 promotes channel closure whereas MgADP binding to SUR1 promotes channel opening. MgADP antagonizes sulphonylurea binding to SUR1 and vice versa; at therapeutic drug concentrations (at which drug binding to SUR1 is nearly saturated), sulphonylurea effect is dominant. The resulting suppression of MgADP activation &#x02018;unmasks&#x02019; the inhibitory effect of ATP on Kir6.2 which enhances that of the sulphonylurea (compare curves obtained for excised patches in nt-free solutions and for intact cells in <bold>A</bold>).</p></caption><graphic xlink:href="bst0430901fig1"/></fig><p>In excised patches, K<sub>ATP</sub> channels undergo rundown, spontaneous decline of channel activity, which consists of a fast, dramatic decrease in current during the first minute after patch excision followed by a subsequent slow phase with a mild decrease in current [<xref rid="B24" ref-type="bibr">24</xref>]. <xref ref-type="fig" rid="F1">Figure 1(</xref>B) illustrates how rundown may affect the direct inhibitory effect of sulphonylureas; it depicts the dependence of the fraction of drug-resistant current on single channel open probability (P<sub>O</sub>) for high-affinity gliclazide inhibition; simulated with a simple concerted gating model [<xref rid="B25" ref-type="bibr">25</xref>]. The value of intrinsic P<sub>O</sub> before rundown (or in the intact cell) is unknown; however, it is likely to be much higher than that during the slow phase of rundown during which experiments are usually conducted (P<sub>O</sub> &#x0223c;0.2&#x02013;0.4) [<xref rid="B24" ref-type="bibr">24</xref>]. Thus, it is important to note that the efficacy of direct sulphonylurea inhibition of K<sub>ATP</sub> channels <italic>in&#x000a0;vivo</italic> is likely to be lower than that obtained from data on excised patches.</p></sec><sec><title>Indirect inhibitory effect of sulphonylureas</title><p>K<sub>ATP</sub> channel activity inside intact pancreatic &#x003b2;-cells is quite low (P<sub>O</sub> &#x0003c; 0.2) [<xref rid="B13" ref-type="bibr">13</xref>] due to the dominant inhibitory effect of large intracellular ATP concentrations. Assuming similar sulphonylurea-binding affinity for nt-bound and nt-free states of the channel, these drugs would produce only partial inhibition of K<sub>ATP</sub> current in intact &#x003b2;-cells (e.g., &#x0223c;80% for gliclazide in <xref ref-type="fig" rid="F1">Figure 1</xref>B). Yet, when sulphonylurea drugs are applied to whole-cell K<sub>ATP</sub> currents in intact cells, the high-affinity inhibition is virtually complete (<xref ref-type="fig" rid="F1">Figure 1</xref>A) [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>].</p><p>Multiple studies demonstrated that the maximal extent of high-affinity sulphonylurea inhibition of K<sub>ATP</sub> channels is enhanced in the presence of MgADP in excised patches [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B30" ref-type="bibr">30</xref>] and studies of this effect eventually led to a postulation of a second, indirect action of sulphonylureas on K<sub>ATP</sub> channel gating (<xref ref-type="fig" rid="F1">Figures 1C</xref> and <xref ref-type="fig" rid="F1">1</xref>D) [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B22" ref-type="bibr">22</xref>]. As well as directly inhibiting the channel, sulphonylurea binding to the high-affinity site also suppresses the activatory effect of MgADP (or MgATP); this in turn &#x02018;unmasks&#x02019; the inhibitory effect of the nt which is then combined with that of the sulphonylurea (<xref ref-type="fig" rid="F1">Figures 1</xref>A, <xref ref-type="fig" rid="F1">1</xref>C and <xref ref-type="fig" rid="F1">1</xref>D).</p><p>More recently, the mechanism of sulphonylureas on K<sub>ATP</sub> channel activation by Mg&#x02013;nts was examined in more detail using K<sub>ATP</sub> channels with a point mutation G334D in the Kir6.2 subunit, Kir6.2&#x02013;G334D/SUR1 channels (<xref ref-type="fig" rid="F2">Figure 2</xref>) [<xref rid="B30" ref-type="bibr">30</xref>]. This mutation severely impairs the inhibitory effect of ATP at Kir6.2 [<xref rid="B30" ref-type="bibr">30</xref>&#x02013;<xref rid="B32" ref-type="bibr">32</xref>] which allows studying the properties of Mg&#x02013;nt activation in isolation from nt inhibition. As shown in <xref ref-type="fig" rid="F2">Figures 2</xref>C and <xref ref-type="fig" rid="F2">2</xref>D, in the presence of 30&#x000a0;&#x003bc;M gliclazide, concentration-activation curves for both MgADP and MgATP on Kir6.2&#x02013;G334D/SUR1 channels are dramatically shifted to the right. In addition, the drug also appears to reduce the maximal extent of the activatory effect of the nts. Detailed analysis of data suggest that the drug both reduces nt binding to SUR1 and impairs the efficacy with which nt binding is transduced into pore opening [<xref rid="B30" ref-type="bibr">30</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><title>Suppression of the stimulatory effect of Mg-nts studied with Kir6.2&#x02013;G334D/SUR1 channels</title><p>(<bold>A</bold> and <bold>B)</bold> Schematic showing effects of nts (<bold>A</bold> and <bold>B</bold>) and of nts and sulphonylureas (<bold>B</bold>) on the Kir6.2&#x02013;G334D/SUR1 channel in which the inhibitory effect of ATP at Kir6.2 is severely impaired. For clarity, all four subunits of the Kir6.2 tetramer but only one SUR1 subunit (out of the four) are shown. MgADP binding to SUR1 promotes channel opening. MgADP antagonizes sulphonylurea binding to SUR1 and vice versa; at therapeutic drug concentrations (at which drug binding to SUR1 is nearly saturated), sulphonylurea effect is dominant. This weakens nt binding and impairs the efficacy with which MgADP binding to SUR1 promotes channel opening (see data depicted in <bold>C</bold> and <bold>D</bold>). (<bold>C</bold> and <bold>D</bold>) Concentration-activation relationships for MgADP (<bold>C</bold>) or MgATP (<bold>D</bold>) for Kir6.2&#x02013;G334D/SUR1 channels in the absence (open circles) or presence (filled circles) of 30&#x000a0;&#x003bc;M gliclazide. The data are taken from Proks et al. [<xref rid="B30" ref-type="bibr">30</xref>]. The lines are the best fit to the mean data of equation: <inline-graphic xlink:href="bst0430901tg3.jpg" id="tg3"/> where EC<sub>50</sub> is the nt concentration at which activation is half maximal, [X] is the test nt concentration, <italic>h</italic> is the Hill coefficient and <italic>a</italic> is the ratio of the maximal stimulatory effect of the nt in the presence and absence of gliclazide. (<bold>C</bold>) EC<sub>50</sub>=9&#x000a0;&#x003bc;M, <italic>h</italic>=1.3; <italic>a</italic> was fixed at 1 (open circles); EC<sub>50</sub>=560&#x000a0;&#x003bc;M, <italic>h</italic>=1.5, <italic>a</italic>=0.3 (filled circles). (<bold>D</bold>) EC<sub>50</sub>=124&#x000a0;&#x003bc;M, <italic>h</italic>=1.3; <italic>a</italic> was fixed at 1 (open circles); EC<sub>50</sub>=8.1&#x000a0;mM, <italic>h</italic>=1.3; <italic>a</italic> was set to 0.3 (filled circles).</p></caption><graphic xlink:href="bst0430901fig2"/></fig><p>Interestingly, a similar effect to gliclazide on MgADP binding and transduction was observed for mutations of either of the Walker A lysines in the catalytic site of the NBS1 or NBS2 of SUR1 [<xref rid="B30" ref-type="bibr">30</xref>]. In contrast, these mutations did not appear to impair MgATP binding. This is consistent with a previous finding that mutations of the Walker A lysines reduce, but do not affect <italic>K<sub>m</sub></italic> values of MgATP hydrolysis in SUR1 [<xref rid="B33" ref-type="bibr">33</xref>]. In addition to altering the maximal extent of high-affinity sulphonylurea block, Mg&#x02013;nts also increase the value of IC<sub>50</sub> for high-affinity drug inhibition [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B25" ref-type="bibr">25</xref>]. This can be attributed to a reciprocal interaction between the two compounds, displacement of sulphonylurea binding by the nt, as previously demonstrated by Hambrock et al. [<xref rid="B34" ref-type="bibr">34</xref>].</p><p>Unlike for SUR1-containing channels, Mg&#x02013;nt activation of K<sub>ATP</sub> channels with the SUR2A regulatory subunit is unaffected by sulphonylureas [<xref rid="B25" ref-type="bibr">25</xref>] and the maximal extent of high-affinity sulphonylurea inhibition of SUR2A-containing channels is reduced, rather than increased in the presence of the nt [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B35" ref-type="bibr">35</xref>]. This may be a contributing factor to a low occurrence of cardiac side effects of sulphonylureas. Reduced sulphonylurea efficacy in this case may be an indirect effect of Mg&#x02013;nts on channel gating (<xref ref-type="fig" rid="F1">Figure 1</xref>B).</p></sec><sec><title>Implications for treatment of neonatal diabetes</title><p>The fact that efficient sulphonylurea inhibition of K<sub>ATP</sub> channels requires the inhibitory effects of nts to be intact is of special significance for treating neonatal diabetes (ND) caused by mutations in the K<sub>ATP</sub> channel [<xref rid="B36" ref-type="bibr">36</xref>].</p><p>ND mutations are found in both Kir6.2 and SUR1 subunits of the K<sub>ATP</sub> channel [<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>]. Most of these mutations impair channel inhibition by ATP either directly, via reducing ATP binding to Kir6.2, or indirectly, via impairing channel gating [<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>]. The latter mutations stabilize the open state of the channel and thus impair channel ability to close both in the absence and in the presence of nts. Both these defects also affect sulphonylurea efficacy to close the K<sub>ATP</sub> channel; mutations that reduce ATP binding to Kir6.2 impair the indirect inhibitory effect of sulphonylureas whereas mutations that impair ATP inhibition indirectly via affecting channel gating reduce both direct and indirect inhibitory effect of sulphonylureas [<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>].</p><p>The ability of sulphonylureas to treat patients with ND caused by mutations in K<sub>ATP</sub> channels depends on the severity of functional defect caused by these mutations. This is illustrated in <xref ref-type="fig" rid="F3">Figure 3</xref> for mutations that impair ATP binding (left, A and C) and channel gating (right, B and D).</p><fig id="F3" position="float"><label>Figure 3</label><caption><title>Gliclazide inhibition of K<sub>ATP</sub> channels with mutations impairing ATP binding (left) and channel gating (right)</title><p>(<bold>A&#x02013;D</bold>) Gliclazide concentration&#x02013;inhibition relations for various mutant channels in the absence (open circles) and presence (filled circles) of various MgATP concentrations. Currents are expressed relative to those in the absence of both MgATP and gliclazide (thus note the different initial current values for different channel mutants in the presence of the nt). The lines are the best fit of the data to the equation: <inline-graphic xlink:href="bst0430901tg4.jpg" id="tg4"/> where <italic>I</italic> is the steady-state K<sub>ATP</sub> current in the presence of the test drug concentration [X], <italic>I</italic><sub>C</sub> is the current in drug free solution obtained by averaging the current before and after application, IC<sub>50</sub> is the drug concentration at which the inhibition is half maximal, <italic>h</italic> is the Hill coefficient, <italic>L</italic> is a scaling factor reflecting the difference between channel activity in control and MgATP-containing solution (<italic>L</italic>=1 in the absence of the nt) and <italic>a</italic> is the fraction of K<sub>ATP</sub> current remaining at gliclazide concentrations that saturate the high-affinity-binding site on SUR1. (<bold>A</bold>) IC<sub>50</sub>=49&#x000a0;nM, <italic>h</italic>=1.2, <italic>a</italic>=0.48 (open symbols); IC<sub>50</sub>=190&#x000a0;nM, <italic>h</italic>=1.2; <italic>a</italic>=0.25, <italic>L</italic>=0.96 (filled symbols). (<bold>B</bold>) IC<sub>50</sub>=200&#x000a0;nM, <italic>h</italic>=0.92; <italic>a</italic>=0.79 (open symbols); IC<sub>50</sub>=140&#x000a0;nM, <italic>h</italic>=0.88, <italic>a</italic>=0.31, <italic>L</italic>=0.77 (filled symbols). (<bold>C</bold>) IC<sub>50</sub>=67&#x000a0;nM, <italic>h</italic>=1.1; <italic>a</italic>=0.39 (open symbols); IC<sub>50</sub>=213&#x000a0;nM, <italic>h</italic>=1.0, <italic>a</italic>=0.39, <italic>L</italic>=2.0 (filled symbols). (<bold>D</bold>) IC<sub>50</sub>=930&#x000a0;nM, <italic>h</italic>=1.5; <italic>a</italic>=0.95 (open symbols); IC<sub>50</sub>=1200&#x000a0;nM, <italic>h</italic>=0.98, <italic>a</italic>=0.38, <italic>L</italic>=0.92 (filled symbols). The data were published previously by Proks et al. [<xref rid="B25" ref-type="bibr">25</xref>]. (<bold>E</bold> and <bold>F</bold>) Comparison of the residual K<sub>ATP</sub> currents in the presence of 100&#x000a0;&#x003bc;M MgATP (<bold>E</bold>) and 1&#x000a0;mM MgATP (<bold>F</bold>) in the absence (open bars) and presence of 30&#x000a0;&#x003bc;M gliclazide (filled bars). Currents are expressed relative to those in the absence of both MgATP and gliclazide. The data were published previously by Proks et al. [<xref rid="B25" ref-type="bibr">25</xref>].</p></caption><graphic xlink:href="bst0430901fig3"/></fig><p>Mutation R201C is located in the putative ATP-binding site; it causes intermediate impairment of ATP inhibition (IC<sub>50</sub>=98&#x000a0;&#x003bc;M) [<xref rid="B25" ref-type="bibr">25</xref>] which results in permanent form of the disease [permanent ND (PNDM)], sometimes also associated with developmental delay (i-DEND syndrome) (intermediate DEND syndrome; ND with developmental delay and epilepsy); [<xref rid="B40" ref-type="bibr">40</xref>]. In the presence of 100&#x000a0;&#x003bc;M MgATP (<xref ref-type="fig" rid="F3">Figure 3</xref>A, filled symbols), suppression of MgATP activation by gliclazide unmasks inhibitory effect of the nt which results in &#x0223c;50% reduction in the gliclazide-resistant current (since 100&#x000a0;&#x003bc;M is close to IC<sub>50</sub> for the inhibitory effect of ATP). Note that there is also a small increase in IC<sub>50</sub> for gliclazide block in the presence of MgATP attributable to displacement of the drug by the nt discussed above.</p><p>ATP-binding mutation G334D almost completely abolishes the inhibitory effect of ATP [<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>]; patients with this mutation have the most severe form of ND with developmental delay and epilepsy (DEND syndrome) [<xref rid="B32" ref-type="bibr">32</xref>]. Since the inhibitory effect of ATP is virtually absent from these channels, maximal extent of high-affinity sulphonylurea inhibition of K<sub>ATP</sub> channels with this mutation is not enhanced by MgATP, even at a physiological concentration of the nt (1&#x000a0;mM; <xref ref-type="fig" rid="F3">Figures 3</xref>C, <xref ref-type="fig" rid="F3">3</xref>E and <xref ref-type="fig" rid="F3">3</xref>F). In contrast, channels with mutation R201C are almost completely inhibited with 1&#x000a0;mM MgATP in the presence of the sulphonylurea (<xref ref-type="fig" rid="F3">Figure 3</xref>F). This explains why sulphonylureas can be used to treat ND in patients with R201C but not G334D mutation [<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B41" ref-type="bibr">41</xref>].</p><p>Intermediate DEND syndrome mutation V59M [<xref rid="B40" ref-type="bibr">40</xref>] impairs gating of the channel and thus suppresses the direct inhibitory effect of gliclazide (<xref ref-type="fig" rid="F1">Figures 1</xref>B and <xref ref-type="fig" rid="F3">3</xref>B, open circles). However, the maximal extent of the sulphonylurea inhibition is greatly enhanced in the presence of 100&#x000a0;&#x003bc;M MgATP as the drug unmasks substantial inhibitory effect of the nt at Kir6.2 (IC<sub>50</sub> for the inhibitory effect of ATP is 62&#x000a0;&#x003bc;M) [<xref rid="B25" ref-type="bibr">25</xref>]. Thus, although inhibition by sulphonylurea alone is poor, these channels can be effectively blocked by the drug in the presence of physiological concentrations of ATP (1&#x000a0;mM, <xref ref-type="fig" rid="F3">Figure 3</xref>F). This is not the case for mutation I296L, which is only partially blocked by gliclazide even in the presence of 3&#x000a0;mM of MgATP (<xref ref-type="fig" rid="F3">Figure 3</xref>D). This mutation causes very strong gating defect that results in DEND syndrome; unlike for V59M, patients with this mutation cannot be treated with sulphonylureas [<xref rid="B42" ref-type="bibr">42</xref>].</p><p>In addition to the defects in ATP inhibition, some mutations in SUR cause ND by enhancing channel activation by Mg&#x02013;nts [<xref rid="B39" ref-type="bibr">39</xref>]. Available data suggest that mutations discovered so far in this category may have either no effect or cause only small reduction in the indirect block of sulphonylureas [<xref rid="B39" ref-type="bibr">39</xref>], which is probably mediated via displacement of the drug from SUR1 by Mg&#x02013;nt binding to NBS2 [<xref rid="B43" ref-type="bibr">43</xref>].</p></sec><sec><title>Concluding remarks</title><p>Effective inhibition of &#x003b2;-cell K<sub>ATP</sub> channels by sulphonylureas requires co-operation from adenosine nts, which are major intracellular modulators of these channels. The same is true for glinides such as repaglinide [<xref rid="B44" ref-type="bibr">44</xref>]. Interestingly, recent data indicate that the collaboration between nts and sulphonylureas extends beyond the K<sub>ATP</sub> channel. Drug-induced stimulation of insulin exocytosis via Epac2 (cAMP-activated guanine-nt exchange factor). It has recently been demonstrated that binding of sulphonylureas to this protein requires cAMP [<xref rid="B45" ref-type="bibr">45</xref>]. Understanding of the molecular mechanisms of action of sulphonylureas thus underlines the importance of studying drug effects within the context of the native cellular environment.</p></sec></body><back><ack><p>We would like to thank Sonja Fantom for technical help with preparing the figures.</p></ack><fn-group><fn fn-type="presented-at"><p>ATP binding cassette transporters: from mechanism to organism: Held at University of Chester, U.K., 16&#x02013;18 April 2015.</p></fn></fn-group><sec><title>Funding</title><p>HdW was supported by the <funding-source id="gs1">European Foundation for the Study of Diabetes (EFSD)</funding-source>. PP was supported by the <funding-source id="gs2">Wellcome Trust</funding-source>.</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="uid1">ABC</term><def><p>ATP-binding cassette</p></def></def-item><def-item><term id="uid2">K<sub>ATP</sub></term><def><p>ATP-sensitive potassium channel</p></def></def-item><def-item><term id="uid3">NBD1/2</term><def><p>nt-binding domain 1/2</p></def></def-item><def-item><term id="uid4">NBS1/2</term><def><p>nt-binding site 1/2</p></def></def-item><def-item><term id="uid5">ND</term><def><p>neonatal diabetes</p></def></def-item><def-item><term id="uid6">nt</term><def><p>nucleotides</p></def></def-item><def-item><term id="uid7">P<sub>O</sub></term><def><p>open probability</p></def></def-item><def-item><term id="uid8">SUR</term><def><p>sulphonylurea receptor</p></def></def-item><def-item><term id="uid9">TM</term><def><p>transmembrane domain</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thul&#x000e9;</surname><given-names>P.M.</given-names></name><name><surname>Umpierrez</surname><given-names>G.</given-names></name></person-group><article-title>Sulfonylureas: a new look at old therapy</article-title><source>Curr. Diab. Rep.</source><year>2014</year><volume>14</volume><fpage>473</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1007/s11892-014-0473-5</pub-id><pub-id pub-id-type="pmid">24563333</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gribble</surname><given-names>F.M.</given-names></name><name><surname>Reimann</surname><given-names>F.</given-names></name></person-group><article-title>Sulphonylurea action revisited: the post-cloning era</article-title><source>Diabetologia</source><year>2003</year><volume>46</volume><fpage>875</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1007/s00125-003-1143-3</pub-id><pub-id pub-id-type="pmid">12819907</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name><name><surname>Rorsman</surname><given-names>P.</given-names></name></person-group><article-title>Electrophysiology of the pancreatic beta-cell</article-title><source>Prog. Biophys. Mol. Biol.</source><year>1989</year><volume>54</volume><fpage>87</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/0079-6107(89)90013-8</pub-id><pub-id pub-id-type="pmid">2484976</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proks</surname><given-names>P.</given-names></name><name><surname>Reimann</surname><given-names>F.</given-names></name><name><surname>Green</surname><given-names>N.</given-names></name><name><surname>Gribble</surname><given-names>F.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>Sulfonylurea stimulation of insulin secretion</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><issue>Suppl 3</issue><fpage>S368</fpage><lpage>S376</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.2007.S368</pub-id><pub-id pub-id-type="pmid">12475777</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renstr&#x000f6;m</surname><given-names>E.</given-names></name><name><surname>Barg</surname><given-names>S.</given-names></name><name><surname>Th&#x000e9;venod</surname><given-names>F.</given-names></name><name><surname>Rorsman</surname><given-names>P.</given-names></name></person-group><article-title>Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K<sup>+</sup> channel-independent action</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><issue>Suppl 1</issue><fpage>S33</fpage><lpage>S36</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.2007.S33</pub-id><pub-id pub-id-type="pmid">11815455</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.L.</given-names></name><name><surname>Katoh</surname><given-names>M.</given-names></name><name><surname>Shibasaki</surname><given-names>T.</given-names></name><name><surname>Minami</surname><given-names>K.</given-names></name><name><surname>Sunaga</surname><given-names>Y.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name><name><surname>Yokoi</surname><given-names>N.</given-names></name><name><surname>Iwasaki</surname><given-names>M.</given-names></name><name><surname>Miki</surname><given-names>T.</given-names></name><name><surname>Seino</surname><given-names>S.</given-names></name></person-group><article-title>The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs</article-title><source>Science</source><year>2009</year><volume>325</volume><fpage>607</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1126/science.1172256</pub-id><pub-id pub-id-type="pmid">19644119</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>Adenosine 5'-triphosphate-sensitive potassium channels</article-title><source>Annu. Rev. Neurosci.</source><year>1988</year><volume>11</volume><fpage>97</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1146/annurev.ne.11.030188.000525</pub-id><pub-id pub-id-type="pmid">2452599</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shyng</surname><given-names>S.</given-names></name><name><surname>Nichols</surname><given-names>C.G.</given-names></name></person-group><article-title>Octameric stoichiometry of the K<sub>ATP</sub> channel complex</article-title><source>J. Gen. Physiol.</source><year>1997</year><volume>110</volume><fpage>655</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1085/jgp.110.6.655</pub-id><pub-id pub-id-type="pmid">9382894</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname><given-names>S.J.</given-names></name><name><surname>Gribble</surname><given-names>F.M.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Trapp</surname><given-names>S.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>Truncation of Kir6.2 produces ATP-sensitive K<sup>+</sup> channels in the absence of the sulphonylurea receptor</article-title><source>Nature</source><year>1997</year><volume>387</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/387179a0</pub-id><pub-id pub-id-type="pmid">9144288</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aittoniemi</surname><given-names>J.</given-names></name><name><surname>Fotinou</surname><given-names>C.</given-names></name><name><surname>Craig</surname><given-names>T.J.</given-names></name><name><surname>de Wet</surname><given-names>H.</given-names></name><name><surname>Proks</surname><given-names>P.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator</article-title><source>Phil. Trans. Royal Soc. Lond.</source><year>2009</year><volume>364</volume><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1098/rstb.2008.0142</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zingman</surname><given-names>L.V.</given-names></name><name><surname>Alekseev</surname><given-names>A.E.</given-names></name><name><surname>Bienengraeber</surname><given-names>M.</given-names></name><name><surname>Hodgson</surname><given-names>D.</given-names></name><name><surname>Karger</surname><given-names>A.B.</given-names></name><name><surname>Dzeja</surname><given-names>P.P.</given-names></name><name><surname>Terzic</surname><given-names>A.</given-names></name></person-group><article-title>Signalling in channel/enzyme multimers: ATPase transitions in SUR module gate ATP-sensitive K<sup>+</sup> conductance</article-title><source>Neuron</source><year>2001</year><volume>31</volume><fpage>233</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(01)00356-7</pub-id><pub-id pub-id-type="pmid">11502255</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Geng</surname><given-names>X.</given-names></name><name><surname>Drain</surname><given-names>P.</given-names></name></person-group><article-title>Open state destabilization by ATP occupancy is mechanism speeding burst exit underlying K<sub>ATP</sub> channel inhibition by ATP</article-title><source>J. Gen. Physiol.</source><year>2002</year><volume>119</volume><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1085/jgp.119.1.105</pub-id><pub-id pub-id-type="pmid">11773242</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarasov</surname><given-names>A.I.</given-names></name><name><surname>Girard</surname><given-names>C.A.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>ATP sensitivity of the ATP-sensitive K<sup>+</sup> channel in intact and permeabilized pancreatic beta-cells</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>2446</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.2337/db06-0360</pub-id><pub-id pub-id-type="pmid">16936192</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergani</surname><given-names>P.</given-names></name><name><surname>Lockless</surname><given-names>S.W.</given-names></name><name><surname>Nairn</surname><given-names>A.C.</given-names></name><name><surname>Gadsby</surname><given-names>D.C.</given-names></name></person-group><article-title>CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains</article-title><source>Nature</source><year>2005</year><volume>433</volume><fpage>876</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/nature03313</pub-id><pub-id pub-id-type="pmid">15729345</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>M.F.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Hwang</surname><given-names>T.C.</given-names></name></person-group><article-title>Stable ATP binding mediated by a partial NBD dimer of the CFTR chloride channel</article-title><source>J. Gen. Physiol.</source><year>2010</year><volume>135</volume><fpage>399</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1085/jgp.201010399</pub-id><pub-id pub-id-type="pmid">20421370</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>M.F.</given-names></name><name><surname>Callaghan</surname><given-names>R.</given-names></name><name><surname>Ford</surname><given-names>R.C.</given-names></name><name><surname>Higgins</surname><given-names>C.F.</given-names></name></person-group><article-title>Structure of the multidrug resistance P-glycoprotein to 2.5&#x000a0;nm resolution determined by electron microscopy and image analysis</article-title><source>J. Biol. Chem.</source><year>1997</year><volume>272</volume><fpage>10685</fpage><lpage>10694</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.16.10685</pub-id><pub-id pub-id-type="pmid">9099718</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>C.</given-names></name><name><surname>Berridge</surname><given-names>G.</given-names></name><name><surname>Mistry</surname><given-names>P.</given-names></name><name><surname>Higgins</surname><given-names>C.</given-names></name><name><surname>Charlton</surname><given-names>P.</given-names></name><name><surname>Callaghan</surname><given-names>R.</given-names></name></person-group><article-title>Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis</article-title><source>Biochemistry</source><year>2000</year><volume>39</volume><fpage>11901</fpage><lpage>11906</lpage><pub-id pub-id-type="doi">10.1021/bi000559b</pub-id><pub-id pub-id-type="pmid">11009602</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vila-Carriles</surname><given-names>W.H.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Bryan</surname><given-names>J.</given-names></name></person-group><article-title>Defining a binding pocket for sulphonylureas in ATP-sensitive potassium channels</article-title><source>FASEB J</source><year>2007</year><volume>21</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1096/fj.06-6730hyp</pub-id><pub-id pub-id-type="pmid">17110465</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashfield</surname><given-names>R.</given-names></name><name><surname>Gribble</surname><given-names>F.M.</given-names></name><name><surname>Ashcroft</surname><given-names>S.J.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K<sub>ATP</sub> channel</article-title><source>Diabetes</source><year>1999</year><volume>48</volume><fpage>1341</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.2337/diabetes.48.6.1341</pub-id><pub-id pub-id-type="pmid">10342826</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000fc;hner</surname><given-names>P.</given-names></name><name><surname>Prager</surname><given-names>R.</given-names></name><name><surname>Stephan</surname><given-names>D.</given-names></name><name><surname>Russ</surname><given-names>U.</given-names></name><name><surname>Winkler</surname><given-names>M.</given-names></name><name><surname>Ortis</surname><given-names>D.</given-names></name><name><surname>Bryan</surname><given-names>J.</given-names></name><name><surname>Quast</surname><given-names>U.</given-names></name></person-group><article-title>Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K<sub>ATP</sub> channel</article-title><source>Naunyn-Schmiedeberg's Arch. Pharmacol.</source><year>2012</year><volume>385</volume><fpage>299</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1007/s00210-011-0709-8</pub-id><pub-id pub-id-type="pmid">22083559</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>A.M.K.</given-names></name><name><surname>Hansen</surname><given-names>J.B.</given-names></name><name><surname>Carr</surname><given-names>R.D.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name><name><surname>Wahl</surname><given-names>P.</given-names></name></person-group><article-title>Kir6.2-dependent high affinity repaglinide binding to beta-cell K<sub>ATP</sub> channels</article-title><source>Br. J. Pharmacol.</source><year>2005</year><volume>144</volume><fpage>551</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706082</pub-id><pub-id pub-id-type="pmid">15678092</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gribble</surname><given-names>F.M.</given-names></name><name><surname>Tucker</surname><given-names>S.J.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K<sup>+</sup> channel currents expressed in <italic>Xenopus</italic> oocytes: a reinterpretation</article-title><source>J. Physiol.</source><year>1997</year><volume>504</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7793.1997.00035.x</pub-id><pub-id pub-id-type="pmid">9350615</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelmoneim</surname><given-names>A.S.</given-names></name><name><surname>Hasenbank</surname><given-names>S.E.</given-names></name><name><surname>Seubert</surname><given-names>J.M.</given-names></name><name><surname>Brocks</surname><given-names>D.R.</given-names></name><name><surname>Light</surname><given-names>P.E.</given-names></name><name><surname>Simpson</surname><given-names>S.H.</given-names></name></person-group><article-title>Variations in tissue selectivity amongst insulin secretagogues: a systematic review</article-title><source>Diabetes. Obes. Metab.</source><year>2012</year><volume>14</volume><fpage>130</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01496.x</pub-id><pub-id pub-id-type="pmid">21923736</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proks</surname><given-names>P.</given-names></name><name><surname>de Wet</surname><given-names>H.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>Activation of the K<sub>ATP</sub> channel by Mg-nucleotide interaction with SUR1</article-title><source>J. Gen. Physiol.</source><year>2010</year><volume>136</volume><fpage>389</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1085/jgp.201010475</pub-id><pub-id pub-id-type="pmid">20876358</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proks</surname><given-names>P.</given-names></name><name><surname>de Wet</surname><given-names>H.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>Molecular mechanism of sulphonylurea block of K<sub>ATP</sub> channels carrying mutations that impair ATP inhibition and cause neonatal diabetes</article-title><source>Diabetes</source><year>2013</year><volume>62</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.2337/db13-0531</pub-id><pub-id pub-id-type="pmid">23258903</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trube</surname><given-names>G.</given-names></name><name><surname>Rorsman</surname><given-names>P.</given-names></name><name><surname>Ohno-Shosaku</surname><given-names>T.</given-names></name></person-group><article-title>Opposite effects of tolbutamide and diazoxide on the ATP-dependent K- channel in mouse pancreatic beta cells</article-title><source>Pfl&#x000fc;gers Arch</source><year>1986</year><volume>407</volume><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1007/BF00657506</pub-id><pub-id pub-id-type="pmid">2431383</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>C.L.</given-names></name><name><surname>Proks</surname><given-names>P.</given-names></name><name><surname>Rodrigo</surname><given-names>G.C.</given-names></name><name><surname>Jones</surname><given-names>P.</given-names></name><name><surname>Hayabuchi</surname><given-names>Y.</given-names></name><name><surname>Standen</surname><given-names>N.B.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M</given-names></name></person-group><article-title>Gliclazide produces high-affinity block of K<sub>ATP</sub> channels in mouse isolated pancreatic &#x003b2;-cells but not rat heart or arterial smooth muscle cells</article-title><source>Diabetologia</source><year>2001</year><volume>44</volume><fpage>1019</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1007/s001250100595</pub-id><pub-id pub-id-type="pmid">11484080</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Z&#x000fc;nckler</surname><given-names>B.J.</given-names></name><name><surname>Lins</surname><given-names>S.</given-names></name><name><surname>Ohno-Shosaku</surname><given-names>T.</given-names></name><name><surname>Trube</surname><given-names>G.</given-names></name><name><surname>Panten</surname><given-names>U.</given-names></name></person-group><article-title>Cytosolic ADP enhances the sensitivity of tolbutamide of ATP-dependent K<sup>+</sup> channels from pancreatic &#x003b2; -cells</article-title><source>FEBS Lett</source><year>1988</year><volume>239</volume><fpage>241</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(88)80925-6</pub-id><pub-id pub-id-type="pmid">3053250</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwanstecher</surname><given-names>C.</given-names></name><name><surname>Dickel</surname><given-names>C.</given-names></name><name><surname>Panten</surname><given-names>U.</given-names></name></person-group><article-title>Cytosolic nucleotides enhance the tolbutamide sensitivity of the ATP-dependent K-channel in mouse pancreatic beta-cells by their combined actions at inhibitory and stimulatory sites</article-title><source>Mol. Pharmacol.</source><year>1992</year><volume>41</volume><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">1545776</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proks</surname><given-names>P.</given-names></name><name><surname>de Wet</surname><given-names>H.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2/SUR1 but not Kir6.2/SUR2A K<sub>ATP</sub> channels: A mechanistic study</article-title><source>J. Gen. Physiol.</source><year>2014</year><volume>144</volume><fpage>469</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1085/jgp.201411222</pub-id><pub-id pub-id-type="pmid">25348414</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drain</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>L.H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>K<sub>ATP</sub> channel inhibition by ATP requires distinct functional domains of the cytoplasmic C terminus of the pore-forming subunit</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>1998</year><volume>95</volume><fpage>13953</fpage><lpage>13958</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.23.13953</pub-id><pub-id pub-id-type="pmid">9811907</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masia</surname><given-names>R.</given-names></name><name><surname>Koster</surname><given-names>J.C.</given-names></name><name><surname>Tumini</surname><given-names>S.</given-names></name><name><surname>Chiarelli</surname><given-names>F.</given-names></name><name><surname>Colombo</surname><given-names>C.</given-names></name><name><surname>Nichols</surname><given-names>C.G.</given-names></name><name><surname>Barbetti</surname><given-names>F.</given-names></name></person-group><article-title>An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>328</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.2337/db06-1275</pub-id><pub-id pub-id-type="pmid">17259376</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wet</surname><given-names>H.</given-names></name><name><surname>Mikhailov</surname><given-names>M.V.</given-names></name><name><surname>Fotinou</surname><given-names>C.</given-names></name><name><surname>Dreger</surname><given-names>M.</given-names></name><name><surname>Craig</surname><given-names>T.J.</given-names></name><name><surname>V&#x000e9;nien-Bryan</surname><given-names>C.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>Studies of the ATPase activity of the ABC protein SUR1</article-title><source>FEBS J</source><year>2007</year><volume>274</volume><fpage>3532</fpage><lpage>3544</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2007.05879.x</pub-id><pub-id pub-id-type="pmid">17561960</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hambrock</surname><given-names>A.</given-names></name><name><surname>L&#x000f6;ffler-Walz</surname><given-names>C.</given-names></name><name><surname>Quast</surname><given-names>U.</given-names></name></person-group><article-title>Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides</article-title><source>Br. J. Pharmacol.</source><year>2002</year><volume>136</volume><fpage>995</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0704801</pub-id><pub-id pub-id-type="pmid">12145099</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>N.</given-names></name><name><surname>Lamp</surname><given-names>S.T.</given-names></name><name><surname>Weiss</surname><given-names>J.N.</given-names></name></person-group><article-title>Sulfonylureas, ATP-sensitive K<sup>+</sup> channels, and cellular K<sup>+</sup> loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle</article-title><source>Circ. Res.</source><year>1991</year><volume>69</volume><fpage>623</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1161/01.RES.69.3.623</pub-id><pub-id pub-id-type="pmid">1908355</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>New uses for old drugs: neonatal diabetes and sulphonylureas</article-title><source>Cell Metab</source><year>2010</year><volume>11</volume><fpage>179</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2010.02.004</pub-id><pub-id pub-id-type="pmid">20197050</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Proks</surname><given-names>P.</given-names></name><name><surname>Clark</surname><given-names>R.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Islam</surname><given-names>S.</given-names></name></person-group><article-title>ATP-sensitive potassium channels in health and disease</article-title><source>Islets of Langerhans</source><year>2015</year><publisher-name>Springer</publisher-name><fpage>305</fpage><lpage>336</lpage></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koster</surname><given-names>J.C.</given-names></name><name><surname>Remedi</surname><given-names>M.S.</given-names></name><name><surname>Dao</surname><given-names>C.</given-names></name><name><surname>Nichols</surname><given-names>C.G.</given-names></name></person-group><article-title>ATP and sulfonylurea sensitivity of mutant ATP-sensitive K<sup>+</sup> channels in neonatal diabetes: implications for pharmacogenomic therapy</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>2645</fpage><lpage>2654</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.9.2645</pub-id><pub-id pub-id-type="pmid">16123353</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proks</surname><given-names>P.</given-names></name></person-group><article-title>Neonatal diabetes caused by activating mutations in the sulphonylurea receptor</article-title><source>Diabetes Metab. J.</source><year>2013</year><volume>37</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.4093/dmj.2013.37.3.157</pub-id><pub-id pub-id-type="pmid">23807917</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>S.E.</given-names></name><name><surname>Edghill</surname><given-names>E.L.</given-names></name><name><surname>Gloyn</surname><given-names>A.L.</given-names></name><name><surname>Ellard</surname><given-names>S.</given-names></name><name><surname>Hattersley</surname><given-names>A.T.</given-names></name></person-group><article-title>Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>1190</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0246-z</pub-id><pub-id pub-id-type="pmid">16609879</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drain</surname><given-names>P.</given-names></name></person-group><article-title>ATP and sulfonylurea linkage in the K<sub>ATP</sub> channel solves a diabetes puzzler</article-title><source>Diabetes</source><year>2013</year><volume>62</volume><fpage>3666</fpage><lpage>3668</lpage><pub-id pub-id-type="doi">10.2337/db13-1194</pub-id><pub-id pub-id-type="pmid">24158995</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proks</surname><given-names>P.</given-names></name><name><surname>Girard</surname><given-names>C.</given-names></name><name><surname>Haider</surname><given-names>S.</given-names></name><name><surname>Gloyn</surname><given-names>A.L.</given-names></name><name><surname>Hattersley</surname><given-names>A.T.</given-names></name><name><surname>Sansom</surname><given-names>M.S.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome</article-title><source>EMBO Rep</source><year>2005</year><volume>6</volume><fpage>470</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7400393</pub-id><pub-id pub-id-type="pmid">15864298</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>D.</given-names></name><name><surname>Voyvodic</surname><given-names>P.</given-names></name><name><surname>Gossack</surname><given-names>L.</given-names></name><name><surname>Quast</surname><given-names>U.</given-names></name><name><surname>Bryan</surname><given-names>J.</given-names></name></person-group><article-title>Two neonatal diabetes mutations on transmembrane helix 15 of SUR1 increase affinity for ATP and ADP at nucleotide binding domain 2</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>17985</fpage><lpage>17895</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.349019</pub-id><pub-id pub-id-type="pmid">22451668</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dabrowski</surname><given-names>M.</given-names></name><name><surname>Wahl</surname><given-names>P.</given-names></name><name><surname>Holmes</surname><given-names>W.E.</given-names></name><name><surname>Ashcroft</surname><given-names>F.M.</given-names></name></person-group><article-title>Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types&#x000a0;of ATP-sensitive potassium channels</article-title><source>Diabetologia</source><year>2001</year><volume>44</volume><fpage>747</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1007/s001250051684</pub-id><pub-id pub-id-type="pmid">11440368</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibasaki</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name><name><surname>Seino</surname><given-names>S.</given-names></name></person-group><article-title>Cooperation between cAMP signalling and sulfonylurea in insulin secretion</article-title><source>Diabetes Obes. Metab.</source><year>2014</year><volume>16</volume><issue>Suppl 1</issue><fpage>S118</fpage><lpage>S125</lpage><pub-id pub-id-type="doi">10.1111/dom.12343</pub-id></element-citation></ref></ref-list></back></article>